Physician profile
Guy Middleton
NPI 1053410993
$2,132.88
in general payments reported to CMS, 2019-2025
30 companies · $182 in 2025
The $182 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $282 · 2021: $306 · 2022: $275 · 2023: $276 · 2024: $314 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $752 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $752.26 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $605.25 | 2019-2023 | |
| Hologic Sales and Service, LLC | $263.40 | 2019-2023 | Coolseal Generator, Acessa Provu System |
| Sumitomo Pharma America, INC. | $193.50 | 2023-2025 | Myfembree, Gemtesa |
| Astellas Pharma US INC | $185.53 | 2019-2025 | Veozah |
| Exeltis, USA INC. | $131.87 | 2021-2025 | Slynd |
| Shield Therapeutics INC | $95.03 | 2023-2025 | Accrufer |
| Scynexis, INC. | $66.53 | 2022 | |
| Pfizer INC. | $59.91 | 2022-2025 | |
| Sage Therapeutics, LLC | $58.45 | 2024-2025 | Zurzuvae |
| Axonics, INC. | $43.10 | 2023 | Axonics |
| Myovant Sciences INC. | $40.42 | 2022 | |
| Solventum Corporation | $39.82 | 2025 | Prevena |
| Therapeuticsmd, INC. | $39.38 | 2019-2021 | |
| Organon LLC | $35.61 | 2023-2024 | Nexplanon |
| Urovant Sciences INC | $35.55 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $35.21 | 2019-2021 | |
| Amgen INC. | $25.82 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.79 | 2019-2022 | |
| Avion Pharmaceuticals | $24.55 | 2019-2020 | |
| Millicent US INC | $20.39 | 2024 | Femring, Intrarosa |
| Bard Access Systems, INC. | $19.34 | 2019 | |
| Dexcom, INC. | $18.77 | 2023 | Dexcom G6 Transmitter |
| Agile Therapeutics, INC. | $14.88 | 2024 | Twirla |
| Duchesnay USA Incorporated | $14.69 | 2019 | |
| Lilly USA, LLC | $14.26 | 2021 | |
| Lupin INC. | $13.89 | 2019 | |
| Medtronic, INC. | $11.94 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guy Middleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.